Business Wire

Asia’s First Private Driving Club “THE MAGARIGAWA CLUB” Scheduled to Open Late 2022 in Tokyo Area

Share

Cornes & Company Ltd. started construction on THE MAGARIGAWA CLUB this past spring in Minamiboso in Chiba Prefecture. In creating the club, Cornes envisions a truly unique driving club, road course, and destination that will offer experiences unattainable at other racing circuits. Located 60minutes from the Tokyo metro area, Tokyo International Airport, and Narita International Airport, the exclusive driving club allows members to enjoy an unparalleled driving experience and spectacular views of Mt. Fuji and Tokyo Bay. In addition to its distinctive 3.5-kilometer driving course, THE MAGARIGAWA CLUB offers recreational options for everyone—not just car enthusiasts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200813005038/en/

Driving Course (Graphic: Business Wire)

Driving Course (Graphic: Business Wire)

The first round of applications for membership are sold out.

Concept

There are a few legendary racetracks in the world today. These spots gain iconic status, becoming destinations for piston-heads. Aiming to put THE MAGARIGAWA CLUB on the map, too, Cornes wants to turn it into an iconic destination by creating an exceptional, world-class driving club.

The name and logomark of the club are based on the kanji “<<<(magarigawa)”. Cornes hopes that MAGARIGAWA’s members will be able to fully immerse themselves in the beautiful natural landscape allowing them to become one with nature and have experiences that they won’t get anywhere else in the world.

Road course

The driving course was designed by the world renown team at Tilke Engineers & Architects. It is the first course in Japan that the team has designed from scratch and features a maximum ascent of 20%, maximum descent of 16%, and an 800-meter long straight, making it a track like no other. It is challenging but also designed for safety, letting drivers focus on the driving experience. Members can drive their automobiles on the course, store them on site, and get maintenance checks before and after driving. They can take one-on-one lessons with professional instructors and explore the potential of their favorite cars in a safe manner. The climate-controlled pit building can accommodate up to 36 vehicles and there are other services and facilities that help ensure a satisfying driving experience.

Other Major Facilities

Clubhouse
The design of the clubhouse combines elements from both traditional Japanese and contemporary architecture. Inside the clubhouse members will find a bar, restaurant, family lounge, gymnasium, 25m swimming pool, spa facilities, and natural hot spring baths. Outside, there is a playground, dog run, and hiking trails.

Owner’s paddocks and long-term garage
Each owner’s paddock provides private indoor parking for up to 4 automobiles and features a spacious floorplan that includes a dining area, living room, and terrace. There is also a long-term car storage facility which is highly secure and climate controlled. On-site mechanics keep members’ vehicles in top condition for driving.

“Magarigawa will be home for car lovers. A sanctuary where members will be able to enjoy and share their passion with friends and family.” said Kenzo Watari, CEO, Cornes Group.
“It will be the answer to the perennial question – where do you drive an 800 horsepower supercar?”

“The extremely hilly topography offers an astonishing basis for the track and makes the layout absolutely unique in the world.” said Dr. Carsten Tilke, Managing Director, Tilke Engineers & Architects. “Although we have designed and realized over 80 racetracks worldwide including 19 Formula One circuits, this project was very special to us and we are proud to be part of it.
Drivers will enjoy mid-speed, technical sections as well as two high-speed straights of the 3.5km track, which incorporates highest safety and environmental standards. It will be ideal for all kinds of driver skills. As a car enthusiast and racing driver myself, I can’t wait to drive my first laps at this amazing unique track.”

For more information, visit www.magarigawa.com.

Overview

Name: THE MAGARIGAWA CLUB
Location: Minamiboso, Chiba Prefecture, Japan
Date of opening: Scheduled for late 2022
Total site area: 1,000,000sq.m
Track specs: 3.5km in length, max. ascent: 20%, max. descent: 16%, 800m long straight, 22 corners, elevation change of 250m
Convenient: 60minutes from Tokyo & Haneda Airport

About Cornes & Company Ltd.

Established in 1861, Cornes & Co., Ltd. specializes in the import and sale of electronic components, systems equipment, industrial machinery, laboratory equipment and scientific instruments, apparels, fragrances, kitchenware, and nautical charts and publications and has expanded its business into a wide range of areas including non-life insurance and marine insurance survey. Its subsidiary companies Cornes Motors Ltd. and C.P.S. Ltd, are authorized distributors of Rolls-Royce, Bentley, Ferrari, Lamborghini, and Porsche automobiles. Cornes Motors is the leading ultra luxury automotive dealership in Japan.

Contact information

Contact for inquiries regarding this matter
Platinum Co., Ltd.
Person in charge: Saori Miyazaki
Email: magarigawa_pr@vectorinc.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ESMO 2020: Cabometyx® (cabozantinib) in Combination With Opdivo® (nivolumab) Demonstrates Significant Survival Benefits in Patients With Advanced Renal Cell Carcinoma in Pivotal Phase III CheckMate -9ER Trial19.9.2020 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the first presentation of results from the pivotal Phase III CheckMate -9ER trial, in which Cabometyx® (cabozantinib) in combination with Bristol Myers Squibb’s Opdivo® (nivolumab) demonstrated significant improvements across all efficacy endpoints, including overall survival (OS), in previously untreated advanced renal cell carcinoma (RCC).1 Cabometyx® in combination with Opdivo® reduced the risk of death by 40% versus sunitinib (HR: 0.60 [98.89% Confidence Interval [CI]: 0.40–0.89]; p= 0.0010; median OS not reached in either arm). In patients receiving Cabometyx® in combination with Opdivo®, median progression-free survival (PFS), the trial’s primary endpoint, was doubled compared to those receiving sunitinib alone: 16.6 months versus 8.3 months respectively (Hazard Ratio [HR]: 0.51 [95% CI 0.41–0.64], p < 0.0001). In addition, Cabometyx® in combination with Opdivo® demonstrated a superior objective response rate, wit

Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EESTPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new

Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EESTPress release

Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95

Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EESTPress release

Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu

Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EESTPress release

Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price

ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom